

DAFTAR PUSTAKA

1. Lia Yunita S, Novia Atmadani R, Titani M. Faktor-faktor Yang Mempengaruhi Pengetahuan Dan Perilaku Penggunaan Antibiotika Pada Mahasiswa Farmasi UMM. *Pharm J Indones*. 2021;6(2):119–23.
2. Nandhini P, Kumar P, Mickymaray S, Alothaim AS, Somasundaram J, Rajan M. Recent Developments in Methicillin-Resistant *Staphylococcus aureus* (MRSA) Treatment: A Review. *Antibiotics*. 2022;11(5):1–21.
3. Sartelli M, Harcastle TC, Catena F, Chichom-Mefire A, Coccolini F, Dhingra S, et al. Antibiotic use in low and middle-income countries and the challenges of antimicrobial resistance in surgery. *Antibiotics*. 2020;9(8):1–12.
4. Siahaan S, Herman MJ, Fitri N. Antimicrobial Resistance Situation in Indonesia: A Challenge of Multisector and Global Coordination. *J Trop Med*. 2022;2022.
5. Andayani R, Faizah AK, Nurrahman NWD, Yusan LY, Putri AK, Praditapuspa EN, et al. Penyuluhan Penggunaan Antibiotik Yang Tepat Dalam Upaya Pencegahan Resistensi Di Kelurahan Wonorejo Surabaya. *J Pengabd Masy Pesisir*. 2022;65–70.
6. Agustin ALD, Ningtyas NSI, Tirtasari K. Resistensi Antibiotik terhadap Bakteri *Escherichia coli* yang Diisolasi dari Ayam Layer di Desa Sesaot Kabupaten Lombok Barat. *Media Kedokt Hewan*. 2022;33(2):87–95.
7. Piewngam P, Otto M. *Staphylococcus aureus* colonisation and strategies for decolonisation. *The Lancet Microbe* [Internet]. 2024;5(6):e606–18. Available from: [http://dx.doi.org/10.1016/S2666-5247\(24\)00040-5](http://dx.doi.org/10.1016/S2666-5247(24)00040-5)
8. Elshenawy RA, Umaru N, Alharbi AB, Aslanpour Z. Antimicrobial stewardship implementation before and during the COVID-19 pandemic in the acute care settings: a systematic review. *BMC Public Health* [Internet]. 2023;23(1):1–24. Available from: <https://doi.org/10.1186/s12889-023->

15072-5

9. Branda F, Scarpa F. Implications of Artificial Intelligence in Addressing Antimicrobial Resistance: Innovations, Global Challenges, and Healthcare's Future. *Antibiotics*. 2024;13(6).
10. Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. *Drug Discov Today* [Internet]. 2019;24(10):2076–85. Available from: <https://doi.org/10.1016/j.drudis.2019.06.014>
11. Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE. Drug repurposing: a systematic review on root causes, barriers and facilitators. *BMC Health Serv Res* [Internet]. 2022;22(1):1–17. Available from: <https://doi.org/10.1186/s12913-022-08272-z>
12. Tripathy S, Sahu SK. FtsZ inhibitors as a new genera of antibacterial agents. *Bioorg Chem* [Internet]. 2019;91:103169. Available from: <https://doi.org/10.1016/j.bioorg.2019.103169>
13. Tovar-nieto AM, Flores-padilla LE, Rivas-santiago B, Trujillo-paez JV, Lara-ramirez EE, Jacobo-delgado YM, et al. The Repurposing of FDA-Approved Drugs as FtsZ Inhibitors against *Mycobacterium tuberculosis* : An In Silico and In Vitro Study. 2024;
14. Rudrapal M, J. Khairnar S, G. Jadhav A. Drug Repurposing (DR): An Emerging Approach in Drug Discovery. *Drug Repurposing - Hypothesis, Mol Asp Ther Appl*. 2020;1–20.
15. Shamim S, Munawar R, Rashid Y, Muhammad Zeshan Qadar S, Bushra R, Begum I, et al. Molecular Docking: An Insight from Drug Discovery to Drug Repurposing Approach. *Unravelling Mol Docking - From Theory to Pract* [Working Title]. 2024;
16. Chen G, Seukep AJ, Guo M. Recent Advances in Molecular Docking for the Research and Discovery of Potential Marine Drugs. *Mar Drugs*. 2020;18(11).

17. Alotaibi BS. Targeting Filamenting temperature-sensitive mutant Z (FtsZ) with bioactive phytoconstituents: An emerging strategy for antibacterial therapy. *PLoS One* [Internet]. 2023;18(8 August):1–17. Available from: <http://dx.doi.org/10.1371/journal.pone.0290852>
18. Gan J hong, Liu J xiang, Liu Y, Chen S wen, Dai W tao, Xiao ZX, et al. DrugRep: an automatic virtual screening server for drug repurposing. *Acta Pharmacol Sin*. 2023;44(4):888–96.
19. Naz F, Mashkoo M, Sharma P, Haque MA, Kapil A, Kumar M, et al. Drug repurposing approach to target FtsZ cell division protein from *Salmonella Typhi*. *Int J Biol Macromol* [Internet]. 2020;159:1073–83. Available from: <https://doi.org/10.1016/j.ijbiomac.2020.05.063>
20. Jonker AH. No Title.
21. Hechtelt Jonker A, Day S, Gabaldo M, Stone H, de Kort M, O'Connor DJ, et al. IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseases. *Nat Rev Drug Discov*. 2023;22(12):937–8.
22. Hamid A, Mäser P, Mahmoud AB. Drug Repurposing in the Chemotherapy of Infectious Diseases. *Molecules*. 2024;29(3):1–17.
23. Chambers HF, DeLeo FR. Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nat Rev Microbiol*. 2009;7(9):629–41.
24. Buckner CA, Lafrenie RM, Dénomée JA, Caswell JM, Want DA. Complementary and alternative medicine use in patients before and after a cancer diagnosis. *Curr Oncol* [Internet]. 2018;25(4):e275–81. Available from: <https://www.intechopen.com/books/advanced-biometric-technologies/liveness-detection-in-biometrics>
25. Boyd NK, Teng C, Frei CR. Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing. *Front Cell Infect Microbiol*. 2021;11(May):1–12.
26. Kumar R, Jagdev G. Repurposing of Drugs Using Network Pharmacology:

- An Exemplar Step in Drug Discovery Linn. *ARC J Pharm Sci.* 2023;8(1):1–6.
27. De Rosa MC, Purohit R, García-Sosa AT. Drug repurposing: a nexus of innovation, science, and potential. *Sci Rep [Internet].* 2023;13(1):1–3. Available from: <https://doi.org/10.1038/s41598-023-44264-7>
28. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. *Pharmaceutics.* 2024;16(3).
29. Afiansyah AG, Mardianto R, Salmasfatah N. Studi In Silico Glibenclamid Sebagai Kandidat Obat Antikanker Pada Inhibitor MAP2K1 dengan Metode Revers Docking. *J Ris Kesehat Poltekkes Depkes Bandung.* 2023;16(1):99–107.
30. Nanda Earlia, Cita Rosita Sigit Prakoeswa, Rinaldi Idroes K. Kajian In Silico dan Aplikasi Klinis Minyak Kelapa Tradisional Aceh Sebagai Terapi Adjuvant Pada Dermatitis Atopik. *Syiah Kuala Univ Press.* 2023;120.
31. Dana, H., Chalbatani, G., Gharagouzloo, E., Memari, F., Rasoolzadeh, R. M. In silico Analysis, Molekular Docking, Molekular Dynamic, Cloning, Expression and Purification of Chimeric Protein in Colorectal Cancer Treatment. *Drug Des Devel Ther.* 2020;14:309–29.
32. Endriyatno NC, Walid M. Studi In Silico Kandungan Senyawa Daun Srikaya (*Annona squamosa L.*) Terhadap Protein Dihydrofolate Reductase Pada *Mycobacterium tuberculosis*. *Pharmacon J Farm Indones.* 2022;19(1):87–98.
33. Foscatto, M and Jensen V. Automated in silico Design of Homogeneous Catalysts. *Am Chem Soc.* 2020;10:2354–2377.
34. Khaerunnisa S. Penelitian in Silico untuk pemula. *Airlangga University Press;* 2020. 112 p.
35. Makatita FA, Wardhani R, Nuraini. Riset in silico dalam pengembangan

sains di bidang pendidikan, studi kasus: analisis potensi cendana sebagai agen anti-aging. *J ABDI*. 2020;2(1):59–67.

36. Gabriell MR, Montolalu RI, Mewengkang HW, Sanger G, Harikedua SD, Makapedua DM, et al. Studi In Silico Senyawa Aktif Daun Tagalolo (*Ficus septica* Burm F) sebagai Ligan Uji pada Enzim L-Histidin Decarboxylase. *Media Teknol Has Perikan* [Internet]. 2022;10(2):122–6. Available from: <https://ejournal.unsrat.ac.id/v3/index.php/jmthp/article/view/40390>
37. Shofi. Studi In silico Senyawa Kuarsetin Daun Kencana Ungu (*Ruellia tuberosa* L.) sebagai Agen Antikanker Payudara. *J Sint Penelit Sains, Ter dan Anal*. 2022;2:1–9.
38. Amin S. Pencarian Kandidat Obat Baru Sebagai Inhibitor Main Protease SARS-CoV-2 Dari Senyawa Aktif Tanaman *Andrographis paniculata*. PT. Literasi Nusantara Abadi Grup; 2024. 124 p.
39. From Ligand-Based Methods to Structure-Based Approaches Computer Aided Drug Design (CADD): Computer Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches. 2022;(June).
40. Ajjarapu SM, Tiwari A, Ramteke PW, Singh DB K. Ligand-based drug designing. *Bioinforma Methods Appl*. 2021;233–52.
41. Sakti Purwanto D, Susanti H, Sugihartini N. Docking Molekuler Potensi Anti Inflamasi Quersetin Daun Kelor (*Moringan oleifera* L.) dengan Autodock-Vina. *J Ilm Mns dan Kesehat* [Internet]. 2021;4(2):2614–3151. Available from: <http://jurnal.umpar.ac.id/index.php/makes>
42. Fauziah A, Fatharani A, Nurawaliah CM, Rivianto FA, Sakina IV, Rahmawati M, et al. Molecular Docking Senyawa Yang Berpotensi Sebagai Antikanker Payudara: Literature Review. *J Pharm Sci*. 2023;6(2):416–27.
43. Awinash C, Ambedkar B, Prafulla S. Molecular docking study and antibacterial activity of novel chalcone derivatives. ~ 39 ~ *Pharma Innov J* [Internet]. 2020;9(1):39–42. Available from:

<http://www.thepharmajournal.com>

44. Meng X-Y, Zhang H-X, Mezei M, Cui M. Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery. *Curr Comput Aided-Drug Des.* 2012;7(2):146–57.
45. Dnyandev KM, Babasaheb GV, Chandrashekhar KV, Chandrakant MA VO. A Review on Molecular Docking. *Int Res J Pure Appl Chem.* 2021;60–8.
46. Ballester PJ MJ. A machine learning approach to predicting protein-ligand binding affinity with applications to Molecular Docking. *Bioinformatics.* 2020;26:1169–75.
47. Setiawan H, Irawan MI. Kajian Pendekatan Penempatan Ligan Pada Protein Menggunakan Algoritma Genetika. *J Sains dan Seni ITS.* 2017;6(2):2–6.
48. Mohanty M, Mohanty PS. Molecular docking in organic, inorganic, and hybrid systems: a tutorial review. *Monatshefte fur Chemie [Internet].* 2023;154(7):683–707. Available from: <https://doi.org/10.1007/s00706-023-03076-1>
49. AP F. Potensi Senyawa Tetrapreniltoluquinone (TPTQ) Dari Tanaman Asam Kandis (*Garcinia cowa Roxb*) Terhadap Ekspresi Beberapa Protein Pada Kanker Secara In Silico. *J Univ Andalas.* 2022;
50. Adrianta KA, Santoso P, Gunawan PW, Pramitha DAI. Interactions of Perisbivalvin, Apioside, and Pelargonidine 3-Sambubioside Against PTGS2 Receptors. *Indones J Pharm Sci Technol.* 2022;9(2):106.
51. Jml QK. EFEKTIVITAS STUDI MOLECULAR DOCKING TERHADAP PENEMUAN OBAT TERBARUKAN. *Fak Kedokteran, Universitas Muhammadiyah Sumatera.* 2022;
52. Endriyatno NC. Molecular Docking of Betel Leaf (*Piper betle L.*) on Protein Dihydrofolate reductase of *Mycobacterium tuberculosis*. *Sci Community Pharm [Internet].* 2022;1(1):1–5. Available from: <https://ojs.stikestelogorejo.ac.id/index.php/scpj/article/view/222%0Ahttps://>

53. Chairunisa U, Eriadi A, Ramadhani P. Studi Uji in Silico Secara Molecular Docking Interaksi Antara Protein Target pada Proses Inflamasi (Kulit Berjerawat) TGF – β 1 (PDB ID: 3tzm) dengan Senyawa Aktif Madecassoside. *J Farm Higea*. 2023;15(2):197.
54. Crampon K, Giorkallos A, Deldossi M, Baud S, Crampon K, Giorkallos A, et al. Machine-learning methods for ligand – protein molecular docking To cite this version : HAL Id : hal-03352012 Machine learning methods for ligand-protein molecular docking. 2023;
55. Bitencourt-Ferreira G, de Azevedo WF. Docking with SwissDock. Vol. 2053, *Methods in Molecular Biology*. 2019. 189–202 p.
56. Muhammed MT, Aki-Yalcin E. Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery. *Lett Drug Des Discov*. 2022;21(3):480–95.
57. Nelson DL, Cox MM, Hoskins AA. Enzyme kinetics as an approach to understanding mechanism. *Lehninger principles of biochemistry*. 2021. 770–822 p.
58. Fujita J, Amesaka H, Yoshizawa T, Hibino K, Kamimura N, Kuroda N, et al. Structures of a FtsZ single protofilament and a double-helical tube in complex with a monobody. *Nat Commun*. 2023;14(1):2–8.
59. Ruiz FM, Huecas S, Santos-Aledo A, Prim EA, Andreu JM, Fernández-Tornero C. FtsZ filament structures in different nucleotide states reveal the mechanism of assembly dynamics. *PLoS Biol*. 2022;20(3):1–22.
60. McQuillen R, Xiao J. Insights into the Structure, Function, and Dynamics of the Bacterial Cytokinetic FtsZ-Ring. *Annu Rev Biophys*. 2020;49:309–41.
61. Gherardi G. Staphylococcus aureus Infection: Pathogenesis and Antimicrobial Resistance. *Int J Mol Sci*. 2023;24(9).

62. Fayisa WO, Tuli NF. Review on Staphylococcus Aureus Enterotoxin. Int J Nurs Care Res [Internet]. 2023;1(2):1–8. Available from: http://biomed.cnjournals.com/ch/reader/download_pdf.aspx?file_no=201501042&year_id=2015&quarter_id=1&falg=1
63. Minter DJ, Appa A, Chambers HF, Doernberg SB. Executive Summary: State-of-The-Art Review: Contemporary Management of Staphylococcus aureus Bacteremia: Controversies in Clinical Practice. Clin Infect Dis [Internet]. 2023;77(11):1489–91. Available from: <https://doi.org/10.1093/cid/ciad525>
64. Brown NM, Goodman AL, Horner C, Jenkins A, Brown EM. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK. JAC-Antimicrobial Resist. 2021;3(1).
65. Shalaby MAW, Dokla EME, Serya RAT, Abouzid KAM. Penicillin binding protein 2a: An overview and a medicinal chemistry perspective. Eur J Med Chem [Internet]. 2020;199:112312. Available from: <https://doi.org/10.1016/j.ejmech.2020.112312>
66. Cao L, Wang L. New covalent bonding ability for proteins. Protein Sci. 2022;31(2):312–22.
67. Boike L, Henning NJ, Nomura DK. Advances in covalent drug discovery. Nat Rev Drug Discov. 2022;21(12):881–98.
68. Alimah, Harun I, Sartika RP. Pengembangan Video Pembelajaran Kimia Pada Materi Ikatan Ion. EduChem. 2023;4(2):1–11.
69. Shi S, Liu Z, Lin Q, Chen X, Kusoglu A. Role of ionic interactions in the deformation and fracture behavior of perfluorosulfonic-acid membranes. Soft Matter. 2020;16(6):1653–67.
70. Siswandono. Kimia Medisinal 1. Surabaya: Airlangga University Press; 2020. 1–590 p p.
71. Scheiner S. Forty years of progress in the study of the hydrogen bond. Struct

- Chem 30. 2020;1119–1128.
72. Scheiner S. The Hydrogen Bond: A Hundred Years and Counting. *J Indian Inst Sci* 100. 2020;61–76.
73. Bian R, Li C, Liu Q, Cao G, Fu Q, Meng P, et al. Recent progress in the synthesis of novel two-dimensional van der Waals materials. *Natl Sci Rev*. 2022;9(5).
74. Tantardini C, Michalchuk AAL, Samtsevich A, Rota C, Kvashnin AG. The Volumetric Source Function: Looking Inside van der Waals Interactions. *Sci Rep* [Internet]. 2020;10(1):1–10. Available from: <http://dx.doi.org/10.1038/s41598-020-64261-4>
75. Sun Q. The Hydrophobic Effects: Our Current Understanding. *Molecules*. 2022;27(20).
76. Silverstein TP. The hydrophobic effect: is water afraid, or just not that interested? *ChemTexts* 6. 2020;26.
77. Bohnert T, Prakash C. ADME Profiling in Drug Discovery and Development: An Overview. *Encycl Drug Metab Interact*. 2012;1–42.
78. Mui Sim DS. Drug absorption and bioavailability. *Pharmacol Basis Acute Care*. 2015;8(1):17–26.
79. Currie GM. Pharmacology, part 2: Introduction to pharmacokinetics. *J Nucl Med Technol*. 2018;46(3):221–30.
80. Tran TT Van, Tayara H, Chong KT. Artificial Intelligence in Drug Metabolism and Excretion Prediction: Recent Advances, Challenges, and Future Perspectives. *Pharmaceutics*. 2023;15(4):1–21.
81. Bolleddula J, Brady K, Bruin G, Lee A, Martin JA, Walles M, et al. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives. *Drug Metab Dispos*. 2022;50(6):837–45.

82. Nataraj N, Rikard SM, Zhang K, Jiang X, Guy GP, Rice K, et al. Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder. *JAMA Netw Open*. 2024;7(4):E244617.
83. Putra PP, Andalas U. Teori dan Tutorial Molecular Docking Menggunakan AutoDock Vina. 2022;(September).
84. 2021 antibacterial agents in clinical and preclinical development: 2021.
85. Chen L, Kashina A, Smith A. Post-translational Modifications of the Protein Termini. 2021;9(July):1–14.
86. Ahlstrom LS, Vorontsov II, Shi J, Miyashita O. Effect of the crystal environment on side-chain conformational dynamics in cyanovirin-N investigated through crystal and solution molecular dynamics simulations. *PLoS One*. 2017;12(1):1–17.
87. Varma AK, Patil R, Das S, Stanley A, Yadav L, Sudhakar A. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of Drug-Designing. *PLoS One*. 2010;5(8).
88. Xiao W, Wang D, Shen Z, Li S, Li H. Multi-body interactions in molecular docking program devised with key water molecules in protein binding sites. *Molecules*. 2018;23(9).
89. Hatami S, Sirous H, Mahnam K, Najafipour A. Preparing a database of corrected protein structures important in cell signaling pathways. 2023;18(February):67–77.
90. Wang J, Liu Y, Tian B. Protein - small molecule binding site prediction based on a pre - trained protein language model with contrastive learning. *J Cheminform* [Internet]. 2024; Available from: <https://doi.org/10.1186/s13321-024-00920-2>
91. Khazanov NA, Carlson HA. Exploring the Composition of Protein-Ligand Binding Sites on a Large Scale. *PLoS Comput Biol*. 2013;9(11).

92. Leis S, Zacharias M. ReFlexIn: A Flexible Receptor Protein-Ligand Docking Scheme Evaluated on HIV-1 Protease. *PLoS One*. 2012;7(10).
93. Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. *J Comput Aided Mol Des*. 2013;27(3):221–34.
94. Brooijmans N, Humblet C. Chemical space sampling by different scoring functions and crystal structures. *J Comput Aided Mol Des*. 2010;24(5):433–47.
95. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: A major update to the DrugBank database for 2018. *Nucleic Acids Res*. 2018;46(D1):D1074–82.
96. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. *J Med Chem*. 2006;49(21):6177–96.
97. Jordaan MA, Ebenezer O, Damoyi N, Shapi M. Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz. *Heliyon* [Internet]. 2020;6(8):e04642. Available from: <http://dx.doi.org/10.1016/j.heliyon.2020.e04642>
98. Matlhodi T, Makatsela LP, Dongola TH, Blessing M, Simelane C, Shonhai A, et al. Auto QSAR-based active learning docking for hit identification of potential inhibitors of Plasmodium falciparum Hsp90 as antimalarial agents. 2024;5:1–23. Available from: <http://dx.doi.org/10.1371/journal.pone.0308969>
99. Du X, Li Y, Xia YL, Ai SM, Liang J, Sang P, et al. Insights into protein–ligand interactions: Mechanisms, models, and methods. *Int J Mol Sci*. 2016;17(2):1–34.

100. Andrei C, Mihai DP, Zanfirescu A, Nitulescu GM, Negres S. In Silico Drug Repurposing Framework Predicts Repaglinide, Agomelatine and Protokylol as TRPV1 Modulators with Analgesic Activity. *Pharmaceutics*. 2022;14(12).
101. Modi PK, Prabhu A, Bhandary YP, Sudheer Shenoy P, Hegde A, Sindhu Priya ES, et al. Effect of calcium glucoheptonate on proliferation and osteogenesis of osteoblast-like cells in vitro. *PLoS One*. 2019;14(9):1–15.
102. Manda G, Rojo AI, Martínez-Klimova E, Pedraza-Chaverri J, Cuadrado A. Nordihydroguaiaretic Acid: From Herbal Medicine to Clinical Development for Cancer and Chronic Diseases. *Front Pharmacol*. 2020;11(February):1–21.
103. McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017;390(10101):1489–98.
104. Xiong L, Zhang H, Guo Y, Song Y, Tao Y. Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. *Front Pharmacol*. 2022;12(January):1–13.
105. Widrich C, Robbins H. Iopamidol: Agent A Non-ionic Contrast Arteriography ' for Peripheral. :53–5.
106. Siebinga H, Robb F, Thomson AH. Population pharmacokinetic evaluation and optimization of amikacin dosage regimens for the management of mycobacterial infections. *J Antimicrob Chemother*. 2020;75(10):2933–40.
107. Masaki RI. Mechanism of action of bortezomib in multiple myeloma therapy. *Int J Myeloma* [Internet]. 2016;6(1):1–6. Available from: http://www.jsm.gr.jp/files/journalpdf/2016_6_1_ri-final.pdf
108. Li C, Sun H, Wei W, Liu Q, Wang Y, Zhang Y, et al. Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. *Cell Oncol*. 2020;43(6):1099–116.

109. Kaul M, Mark L, Zhang Y, Parhi AK, Lyu YL, Pawlak J, et al. TXA709, an FtsZ-targeting benzamide prodrug with improved pharmacokinetics and enhanced in vivo efficacy against methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2015;59(8):4845–55.
110. Nursamsiar N, M. Mangande M, Awaluddin A, Nur S, Asnawi A. In Silico Study of Aglycon Curculigoside A and Its Derivatives as α -Amilase Inhibitors. *Indones J Pharm Sci Technol*. 2020;7(1):29.
111. Xie NZ, Du QS, Li JX, Huang RB. Exploring strong interactions in proteins with quantum chemistry and examples of their applications in drug design. *PLoS One*. 2015;10(9):1–19.
112. Kumar K, Woo SM, Siu T, Cortopassi WA, Duarte F, Paton RS. Cation- π interactions in protein-ligand binding: Theory and data-mining reveal different roles for lysine and arginine. *Chem Sci*. 2018;9(10):2655–65.
113. Liang Z, Li QX. π -Cation Interactions in Molecular Recognition: Perspectives on Pharmaceuticals and Pesticides. *J Agric Food Chem*. 2018;66(13):3315–23.
114. Qiu S, Azofra LM, MacFarlane DR, Sun C. Hydrogen bonding effect between active site and protein environment on catalysis performance in H₂-producing [NiFe] hydrogenases. *Phys Chem Chem Phys*. 2018;20(9):6735–43.
115. Bittermann K, Goss KU. Predicting apparent passive permeability of Caco-2 and MDCK cell-monolayers: A mechanistic model. *PLoS One*. 2017;12(12):1–20.
116. Wei M, Zhang X, Pan X, Wang B, Ji C, Qi Y, et al. HobPre: accurate prediction of human oral bioavailability for small molecules. *J Cheminform* [Internet]. 2022;14(1):1–11. Available from: <https://doi.org/10.1186/s13321-021-00580-6>
117. Tong X, Wang D, Ding X, Tan X, Ren Q, Chen G, et al. Blood–brain barrier

- penetration prediction enhanced by uncertainty estimation. *J Cheminform* [Internet]. 2022;14(1):1–16. Available from: <https://doi.org/10.1186/s13321-022-00619-2>
118. Garrido A, Lepailleur A, Mignani SM, Dallemagne P, Rochais C. hERG toxicity assessment: Useful guidelines for drug design. *Eur J Med Chem* [Internet]. 2020;195:112290. Available from: <https://doi.org/10.1016/j.ejmech.2020.112290>
119. Amengor CDK, Orman E, Danquah CA, Ben IO, Biniyam PD, Harley BK. Pyridine-N-Oxide Alkaloids from *Allium stipitatum* and Their Synthetic Disulfide Analogs as Potential Drug Candidates against *Mycobacterium tuberculosis*: A Molecular Docking, QSAR, and ADMET Prediction Approach. *Biomed Res Int*. 2022;2022.
120. Saito H, Shudo I. Time course observation on protokylol distribution in rats following protokylol administration. *Japan J Pharmacol*. 1972;22(1):97–102.
121. Li S, Zhou Y, Yan Y, Qin Y, Weng Q, Sun L. Structure-Based Virtual Screening, ADMET Properties Prediction and Molecular Dynamics Studies Reveal Potential Inhibitors of *Mycoplasma pneumoniae* HPrK/P. *Life*. 2024;14(6).

